Wednesday, August 16, 2023
Why Is Design Therapeutics Stock Moving Lower Today?
Aug. 15, 2023, Design Therapeutics planned to reformulate its Friedreich ataxia drug following injection site reactions in a Phase 1 study.
The company plans to begin a new multiple-dose Phase 1 study in the second half of 2024, with initial data in the first half of 2025.
Based on current methods and procedures, the treatment effect of DT-216 on FXN protein was inconclusive due to high intra-individual variability, consistent with what was seen in the observational study.
